7-Jan-2026
ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
PRNewswire (Thu, 8-Jan 7:15 AM ET)
Globe Newswire (Tue, 6-Jan 11:56 AM ET)
ADC Therapeutics Announces New Employee Inducement Grant
PRNewswire (Fri, 2-Jan 4:05 PM ET)
Market Chameleon (Thu, 4-Dec 5:08 AM ET)
PRNewswire (Wed, 3-Dec 7:30 AM ET)
ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial
PRNewswire (Tue, 2-Dec 4:05 PM ET)
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
PRNewswire (Mon, 1-Dec 4:05 PM ET)
ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update
PRNewswire (Mon, 10-Nov 7:30 AM ET)
ADC Therapeutics to Host Third Quarter 2025 Financial Results Conference Call on November 10, 2025
PRNewswire (Mon, 3-Nov 7:15 AM ET)
ADC Therapeutics to Present at November Investor Conferences
PRNewswire (Mon, 27-Oct 7:15 AM ET)
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
Adc Therapeutics SA Common Shares trades on the NYSE stock market under the symbol ADCT.
As of January 7, 2026, ADCT stock price climbed to $3.65 with 808,028 million shares trading.
ADCT has a beta of 1.89, meaning it tends to be more sensitive to market movements. ADCT has a correlation of 0.13 to the broad based SPY ETF.
ADCT has a market cap of $452.15 million. This is considered a Small Cap stock.
Last quarter Adc Therapeutics SA Common Shares reported $16 million in Revenue and -$.19 earnings per share. This fell short of revenue expectation by $-89,202 and exceeded earnings estimates by $.19.
In the last 3 years, ADCT traded as high as $6.04 and as low as $.36.
The top ETF exchange traded funds that ADCT belongs to (by Net Assets): IWM, IWO, IBB, VTWO, VFMO.
ADCT has outperformed the market in the last year with a price return of +82.5% while the SPY ETF gained +18.4%. However, in the short term, ADCT had mixed performance relative to the market. It has underperformed in the last 3 months, returning -15.3% vs +3.4% return in SPY. But in the last 2 weeks, ADCT shares have fared better than the market returning +3.4% compared to SPY -0.1%.
ADCT support price is $3.36 and resistance is $3.72 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ADCT shares will trade within this expected range on the day.